© 2026 Sinochem Nanjing Corporation,
All Right Reserved
World War II marked a turning point in medical science. With the rampant spread of infections, penicillin got much of the attention, but the battle against bacteria needed more tools. Nalidixic acid changed the course of urinary tract infection treatment. It didn’t come out of nowhere: scientists investigated the chemical byproducts left behind after the synthesis of chloroquine, the famous antimalarial. Instead of tossing away residue from their experiments, researchers dug deeper and spotted surprising antibacterial effects. By 1962, nalidixic acid hit the scene as the first synthetic quinolone, opening the door to a brand-new class of antibiotics. It didn’t just help patients; it sparked a rush of research and development, turning a once-overlooked chemical byproduct into a pivotal medical product. Doctors quickly discovered it worked best on urinary tract infections, changing how these stubborn ailments got treated and lowering complications worldwide.
Nalidixic acid doesn’t blend in with most drugs found in a pharmacy. As a first-generation quinolone antibiotic, its chemistry gave it a distinct place compared to penicillins, sulfa drugs, or tetracyclines. Unlike broad-spectrum antibiotics wiping out a wide range of pathogens, nalidixic acid sided with tackling Gram-negative bacteria, especially Escherichia coli, Proteus, and other urinary tract invaders. A bottle might contain shining white or pale yellow crystalline powder, usually labeled just “nalidixic acid” or sometimes “Acide nalidixique,” among others, depending on where you look in the world. Its formula, C12H12N2O3, barely changed over the decades, emphasizing its core utility.
Nalidixic acid has a stubborn nature. The crystals don’t dissolve easily in cold water, but mix it in a bit of alkaline solution and the compound cooperates, showing solubility that opens the door to oral suspension formulations. It melts at roughly 225°C, which tells us it handles routine storage pretty well. The substance doesn’t spread a strong odor, making laboratory handling straightforward. Besides looking at the fine yellowish powder and measuring melting points, chemists often rely on NMR and IR spectra for identity confirmation, ensuring pharmaceutical batches don’t go astray and patient safety stays front and center.
Packing and labeling nalidixic acid means following tight standards. Pharmacopoeias, such as the USP or the European Pharmacopeia, call for purity levels above 98%. Impurities can’t creep above the set thresholds, and moisture content must stay minimal to prevent breakdown or clumping. Tablets and capsules need precise mg counts, usually 500 mg per dose in modern formulations. Labels highlight the batch number, expiration date, storage guidance, and country-specific regulations. If you look at older packages, they often display synonyms like “1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid,” showing how chemistry language evolves over decades.
The traditional preparation of nalidixic acid starts from readily available precursors such as ethyl anthranilate. Through a sequence of condensation, cyclization, and oxidation, the synthesis works up through 1,8-naphthyridine intermediates. Oxidation gives the crucial 4-oxo group on the core, while carboxylation at position three nails down the molecule’s antibiotic punch. Technicians blend careful temperature control and pure reagents to avoid side reactions, because any shortcut can introduce impurities that could harm patients. Later refinements in the process swapped out hazardous solvents and added filtration techniques for cleaner yields and safer handling in manufacturing plants.
Nalidixic acid’s structure provides space for creative chemical exploration. Chemists tinker with its side chains to create newer-generation drugs like norfloxacin or ciprofloxacin. Each tweak—say, adding a fluorine atom or swapping an ethyl for a cyclopropyl—results in changes in antibacterial range, absorption, or resistance profiles. While nalidixic acid itself offers direct bactericidal action by interfering with DNA gyrase, modifications in its backbone help expand the war against bacterial resistance. Laboratories worldwide continue to test out analogues, using classic organic reactions such as halogenation, alkylation, and esterification to spin out compounds that respond better to multi-drug resistant pathogens.
Nalidixic acid has gone by many names since chemists first reported it. Synonyms like Acide nalidixique, Negram, Neggram, and Naligram show up on blister packs and vials around the globe. Chemists and pharmacists often reference it by its full chemical title—1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid—for precision or documentation. Each market, each regulatory agency pushes local producers to use updated IUPAC names or brand labels, but unmistakably, product uses and safety profiles tie back to the same core parent structure.
Direct contact or inhalation of nalidixic acid dust causes irritation, which is why operators suit up with gloves and face masks during bulk handling. Pharmaceutical-grade facilities track particulate exposure under strict tolerances. The compound doesn’t pose a high environmental hazard under controlled conditions, but disposal requires following hazardous waste guidelines. Labels include allergy warnings, because hypersensitivity leads to rashes or more serious complications in rare cases. Storage advice focuses on cool, dry conditions and light protection, as moisture and direct sunlight spur breakdown. Healthcare providers track side effects such as gastrointestinal discomfort, headache, and—uncommonly—seizure risk in children or those with kidney issues, reinforcing the need for clinical judgment in every prescription.
Pharmacists and doctors have focused on nalidixic acid for urinary tract infections, especially simple, community-acquired ones. Its oral bioavailability puts it in tablet and suspension form, making it easy for adult and pediatric dosing, although current guidelines lean toward newer quinolones when resistance rates spike. Hospital laboratories test urine samples using discs soaked in nalidixic acid to pinpoint bacterial identity, adding to its diagnostic role. Outside medicine, the compound sees rare use in veterinary practice for urinary infections in companion animals, though vets move to safer alternatives when possible. This targeted application limited the rise of heavy resistance in the early years, but sustained use means antibiotic stewardship policies deal with nalidixic acid as part of stewardship education.
The microbiology lab tells a story of constant adaptation. Nalidixic acid, once king of the hill for urinary bugs, faces growing resistance. Researchers respond by screening derivatives and blends, looking for formulas that keep the door closed to E. coli mutations. Pharmaceutical companies invest in studies mapping out the exact binding interactions between nalidixic acid and bacterial DNA gyrase, which informs the next generation of antibiotics. Universities contribute by running surveillance networks, collecting real-world data from patients and wastewater to track changes in effectiveness and resistance patterns. By feeding this knowledge into the design phase, scientists work to outflank resistant bacteria before they spread through hospital wards.
Nalidixic acid brings benefits, but toxicity researchers know trouble spots. Animal studies and post-marketing surveillance link overdoses to neurological effects—convulsions, hallucinations, and, less commonly, metabolic upsets causing hemolytic anemia in certain enzyme-deficient individuals. Regulatory agencies require companies to report all adverse events, shaping guidelines about which patients qualify for treatment and which ones face higher risk. Toxicology labs develop better assays to detect the drug in plasma and urine, allowing emergency services to respond faster in acute poisoning. Awareness drives in hospitals push practitioners to weigh risks, especially in pregnant women, nursing mothers, and infants below three months, keeping use focused and controlled.
The horizon for nalidixic acid depends on finding new ways to beat antibiotic resistance. While new drugs grab headlines, old compounds like nalidixic acid don’t just fade away. Formulation specialists experiment with nano-encapsulation and prodrug strategies to improve targeted delivery while lowering side effects. Geneticists analyze bacterial genomes for new weaknesses, hoping to combine old-guard drugs like nalidixic acid with next-generation agents. Collaboration across disciplines—microbiology, organic chemistry, clinical medicine—shapes policies and priorities for research funding, aiming for practical, affordable antibiotics that meet needs in resource-limited settings. The legacy of nalidixic acid stands as a reminder that solutions often come from paying attention to what gets left behind in the lab, and how science, when guided by experience and urgent need, turns the unexpected into everyday medicine.
Nalidixic acid, a name that pops up less than it used to, once carried serious weight in a doctor’s office. Developed back in the 1960s, nalidixic acid showed up as a powerful tool against certain bacterial infections, especially urinary tract infections (UTIs). The drug falls under the quinolone class—early days for an antibiotic that tackles bacteria by disrupting their DNA replication. Not many folks realize that the antibiotics most people take now, like ciprofloxacin, actually trace back to nalidixic acid. It’s a pioneer that paved the way, but one does not find it used as often these days due to safety and resistance concerns.
Doctors relied on nalidixic acid for treating acute and uncomplicated UTIs, mainly in adults. The bacteria responsible for UTIs, including Escherichia coli, often responded well to this medicine. As someone who’s navigated a UTI or two, you don’t forget the misery. Having something that works against that pain meant a lot. Quick action against the bacteria could get people back on their feet within a couple days, which matters when daily life and work don’t pause for infections.
Helping people with infections sounds simple, but the story doesn’t end there. Over the years, nalidixic acid started losing ground because bacteria grew crafty. Resistance crept up fast. Even back in the late 1970s, studies noted more frequent treatment failures and a rise in resistant strains worldwide. For a doctor, watching an old standby slip away forces tough choices. Plus, the side effects—nausea, vomiting, rashes, even some trouble for folks with kidney issues—made safer and more modern options look better.
Kids rarely get nalidixic acid today, since the risk of joint issues goes up. Regulatory agencies like the US FDA and the European Medicines Agency flagged concerns about its safety in children and those with existing health conditions. All this means doctors approach it cautiously, leaning into newer drugs whenever possible.
People sometimes ask why anyone should care about a fading drug. Knowledge matters, especially with antibiotics. Nalidixic acid shows what happens when a strong tool gets overused, or when bugs outsmart medicine. Tens of thousands still die each year across the globe from drug-resistant infection. One does not forget lessons like that. Every antibiotic in the toolkit counts, and old drugs occasionally still serve as back-up when nothing else is left.
Solutions start with changing habits. As a patient, it makes sense to ask doctors why they pick certain medicines and to follow instructions. From the prescriber’s side, choosing antibiotics based on evidence—and not just habit—can slow down resistance. Scientists need support to develop new treatments, but it also pays to remember useful old ones if newer options fail. Documenting the drawbacks and strengths of drugs like nalidixic acid gives medicine a solid foundation for future choices.
So, nalidixic acid sticks around as both a warning and an inspiration. Every pill we take, and each prescription written, should draw on the best knowledge available. That way, old lessons don’t go to waste.
Nalidixic acid treats urinary tract infections and fights bacteria that cause those infections. People often trust antibiotics to clear infections quickly. Yet, every medication brings along possible downsides. With nalidixic acid, some reactions are more common or cause more worry than others.
As an antibiotic taken by mouth, nalidixic acid can upset the stomach. Many people who have used it report nausea—sometimes enough to make eating difficult for a few days. Other digestive problems like vomiting, diarrhea, or abdominal pain appear in a chunk of users. For kids, these stomach issues can feel overwhelming, especially if they've never had antibiotics before. Plain, bland foods sometimes help, and staying hydrated is essential for anyone facing these side effects.
Allergic reactions remain rare but grab attention right away. Itching skin or a rash may appear after a dose or two. Some rashes can look alarming, spreading quickly. Hives or swelling, especially on the lips or around the eyes, can signal a more dangerous allergy. Immediate reactions call for stopping the drug and getting checked by a doctor. Health records show that some members of the community with a history of allergies should let their healthcare provider know before starting nalidixic acid.
Most antibiotic courses pass without much impact on mood or nerves. Nalidixic acid, though, sometimes stirs up headaches. Dizziness isn’t unusual, and a small number of patients lose their sense of balance or feel confused. In rare cases, people taking nalidixic acid have experienced hallucinations or even seizures. Older adults face a higher risk for these serious effects, especially those already living with kidney or liver problems. My neighbor, an older woman with a history of mild confusion, once needed a hospital trip after feeling increasingly disoriented on this medication. Her family never expected an antibiotic to cause this much trouble.
Pediatricians shy away from nalidixic acid for young children when other options exist. The reason comes down to unique reactions—some very young kids develop increased pressure in the brain (pseudotumor cerebri), which can cause headaches and vision changes. Medical journals describe how blurred vision or seeing flashes calls for urgent follow-up, even if the eye exam looks fine. Grown-ups might also notice problems like double vision or trouble focusing their eyes, though most won’t long after quitting the medication.
Communication with healthcare providers makes all the difference. Always list out allergies and current medications. Drinking extra water supports kidney health while on nalidixic acid. Promptly reporting stomach pain that doesn’t disappear, persistent rashes, or any new confusion or vision problems helps avoid complications. If another antibiotic will work, doctors might choose it for folks who’ve run into trouble before. Listening to your body, reading the medication instructions, and bringing problems to your clinician's attention builds a safer road for recovery from infection.
Doctors face a tough call with antibiotics and pregnancy. My time working in a community pharmacy taught me this up close. Pregnant women come in worried about every pill, asking what risks the baby may face. They deserve careful answers. Nalidixic acid, an older antibiotic, stands out in these conversations because it’s not a go-to choice anymore. The US FDA classified nalidixic acid as a pregnancy Category C drug. That basically means animal research found some problems for unborn babies, but there’s no confirmed data for people. Decisions here rely on weighing risks and real need.
Animal studies showed nalidixic acid can cause joint problems in developing babies, especially those affecting weight-bearing joints. The concern isn’t just laboratory theory. Health authorities like the CDC and World Health Organization have steered health care workers away from quinolones like nalidixic acid for pregnant women unless nothing else works.
Quinolone antibiotics affect cartilage development in animal infants. Human data is harder to come by, since doctors don’t want to take chances in a high-risk group. Out of the few cases where the drug reached an unborn baby, doctors couldn’t rule out harm. There’s also the problem of resistance. Nalidixic acid doesn’t cover a broad range of bugs anymore, so doctors have found safer and more effective options. Guidelines highlight amoxicillin, nitrofurantoin, or cephalexin over older options like nalidixic acid if a pregnant woman needs treatment for urinary tract infections.
Nursing mothers face a different set of risks. Nalidixic acid passes into breast milk. The amounts found in milk are low, but most experts still tell mothers to avoid this drug while breastfeeding if there’s another safe option. Babies feeding on milk with nalidixic acid may develop blood problems like hemolytic anemia, which sometimes shows up in newborns already at risk due to inherited issues. This isn’t just theory; cases have been reported in medical journals. In busy clinics, I’ve seen pediatricians switch new mothers away from quinolones as soon as they find out a safer alternative exists.
Healthy pregnancies and healthy babies come from clear conversations and trust between patients and doctors. Expecting mothers and women who breastfeed must feel empowered to ask about every prescription. Peer-reviewed guidelines offer the most up-to-date information, but they don’t replace clinical judgement and personal values. If someone develops a serious infection resistant to most medications, then specialists weigh every option—including older drugs like nalidixic acid. Hospital teams call in infectious disease experts and pediatricians to run through all scenarios.
I've watched families walk into pharmacies scared about antibiotics and leave certain about what’s safe. That only happens with honest talk and decisions based on real evidence, not just habit or hearsay. Newer antibiotics exist for a reason—they've shown better safety and fewer surprises for mothers and their babies.
Anyone wondering about a prescription during pregnancy or breastfeeding should ask their healthcare team to share the latest recommendations from trusted organizations: the American College of Obstetricians and Gynecologists, the Centers for Disease Control, and the World Health Organization. Reliable online resources such as LactMed and Drugs.com give updated information for families looking for plain language answers.
Care teams improve lives by staying cautious with old drugs like nalidixic acid when better, safer choices are available. That isn’t just about following rules; it’s about caring deeply for families at a vulnerable time.
Nalidixic acid isn’t the flashiest drug on the shelf, but it’s shown its use for decades, especially in treating urinary tract infections caused by certain bacteria. Growing up in a home where someone seemed to always be fighting UTIs, I saw prescriptions like this more times than I can count. This medication has been around since the 1960s—right about the time when doctors realized not every infection needed penicillin. No one should start this drug without a doctor’s say-so. Like all antibiotics, using it wrong can open the door to bigger problems like resistance.
The daily routine with nalidixic acid matters. For adults, doctors often advise a dose of about 1 gram taken four times each day, spaced evenly. Swallowing the pill with a full glass of water seems simple, but makes a real difference, especially for the kidneys. Younger folks get a dose based on body weight—a detail a responsible parent or caregiver shouldn’t ignore. Some parents try to cut corners, guessing by splitting tablets or estimating doses, but this is exactly where trouble can start. Too little can waste time and leave bacteria living in a half-cured state, primed for trouble.
Nalidixic acid tends to work best on an empty stomach, about an hour before or two hours after meals. Many people forget the food part, thinking it won’t matter if it’s gobbled down with a heavy lunch. Sticking to those windows helps the drug break down and get to work. Skipping or missing doses can get in the way of healing, but doubling up on the next dose is a risky game. If you miss one, just pick up with the next scheduled dose. It seems simple, but nobody remembers perfectly without reminders—set alarms if you have to.
Everyone hears about side effects yet few people talk openly about what happens in day-to-day life. Nalidixic acid can cause nausea, headache, or visual changes—these are not just numbers on a list; I saw my uncle get blurry vision for a day before his doctor sorted things out. Kids often react differently, so watching them for confusion or sensitivity to light also matters. If joints hurt or convulsions set in, stop and call the clinic immediately. Reporting any strange effects lets medical folks catch bad reactions early, not after weeks of extra pain.
Doctors don’t prescribe nalidixic acid just to clear up a fever or sniffle; it works specifically against certain bacteria, not viral bugs. People often push for antibiotics because being sick feels awful, but taking unneeded doses does more harm than good, especially for our families down the road. Antimicrobial resistance circles back—what works today may not work a few years from now if everyone misuses drugs or quits their course halfway in. Pharmacists and doctors team up not to make your life harder, but to keep you and everyone else safer in the future.
If confusion hits about how much or how often to take nalidixic acid, reach out to a healthcare provider and double-check. Packaging instructions don’t always speak clearly, and it’s easy to assume you’re right until symptoms linger. Clear conversations with your doctor or pharmacist save frustration and money, sparing everyone from repeat illnesses and stronger germs. While newer antibiotics get most of the headlines, nalidixic acid can still help when used wisely, with respect for dosage, timing, and the advice of professionals who've seen the consequences play out up close.
Doctors often prescribe nalidixic acid to fight urinary tract infections, especially when more common antibiotics fail or can’t be used. This medicine belongs to a group called quinolones. Like its cousins, nalidixic acid can cross paths with other medications in unpredictable ways. Nobody wants to see more trouble pop up from a cure that should help.
Mixing drugs without checking for interactions can lead to some unpleasant—and sometimes dangerous—side effects. I’ve seen patients develop strange muscle twitches or even fast, irregular heartbeats, simply because their medications didn’t play nice together. Let’s dig into some combinations that can cause trouble.
People on blood thinners, especially warfarin, have a real reason to pay attention. Nalidixic acid changes how the body handles warfarin, leading to bleeding risk. Studies show that the interaction raises warfarin levels, sometimes to double what’s safe. Hospital labs pick up on this problem all the time with patients who land in the emergency room after starting an antibiotic.
Another group that faces a risk: children or anyone on anti-seizure drugs like phenytoin or phenobarbital. Nalidixic acid can lower the threshold for seizures, and that spells big trouble. Some children who had been seizure-free began having breakthrough episodes after taking nalidixic acid.
Antacids with lots of aluminum, calcium, or magnesium can block nalidixic acid from working. The science here is pretty clear: these minerals stop the drug from getting absorbed, so the infection ends up sticking around longer. The more antacids people take, the less likely their antibiotic does its job. Doctors and pharmacists usually warn patients to separate doses by several hours, but busy schedules lead to forgetfulness and gaps in treatment.
Transparent communication between patients, nurses, and doctors saves lives. I always remind people to bring an up-to-date list of every pill, vitamin, or supplement they’re taking. Technology can help catch interactions, but nothing replaces a detailed medication review by a sharp-eyed clinician.
Regular blood work goes a long way for anyone juggling blood thinners and antibiotics. If a new medicine gets prescribed, doctors should test how quickly blood is clotting within a few days. If things look off, a quick dose adjustment heads off disaster.
Clear instructions matter most. Whenever someone needs both nalidixic acid and antacids, the doctor or nurse should lay out a simple schedule. It’s no good telling people to “take separately”—they need to hear, “drink your antibiotic at breakfast, wait at least two hours before any heartburn relief.” That plain language prevents skipped doses and makes the difference between getting better or landing back in a hospital bed.
Every year, the FDA receives reports about poor outcomes tied to these sorts of drug combinations. Simple slip-ups can bring unfortunate results. Nobody wants family members to struggle because of a preventable mix-up. The science is there, the warnings are clear—steady follow-through keeps everyone safer.
| Names | |
| Preferred IUPAC name | 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid |
| Other names |
Neggram Naligram Negram Nalidix Vagran Nevigramon |
| Pronunciation | /ˌnælɪˈdɪksɪk ˈæsɪd/ |
| Identifiers | |
| CAS Number | 389-08-2 |
| Beilstein Reference | 146506 |
| ChEBI | CHEBI:7659 |
| ChEMBL | CHEMBL144 |
| ChemSpider | 5468 |
| DrugBank | DB00779 |
| ECHA InfoCard | ECHA InfoCard: 100.002.796 |
| EC Number | 211-051-7 |
| Gmelin Reference | 8787 |
| KEGG | C07309 |
| MeSH | D009296 |
| PubChem CID | 4416 |
| RTECS number | QT0525000 |
| UNII | 7SJO0WDW4E |
| UN number | UN2580 |
| CompTox Dashboard (EPA) | DJ0JB6OFO9 |
| Properties | |
| Chemical formula | C12H12N2O3 |
| Molar mass | 250.24 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.71 g/cm3 |
| Solubility in water | Very slightly soluble in water |
| log P | 0.14 |
| Vapor pressure | 1.57E-8 mmHg at 25°C |
| Acidity (pKa) | pKa = 6.0 |
| Basicity (pKb) | 2.4 |
| Magnetic susceptibility (χ) | -73.0e-6 cm³/mol |
| Refractive index (nD) | 1.695 |
| Dipole moment | 3.98 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | NaN |
| Std enthalpy of formation (ΔfH⦵298) | -727.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3687 kJ/mol |
| Pharmacology | |
| ATC code | J01MB02 |
| Hazards | |
| GHS labelling | GHS labelling of Nalidixic Acid: `Warning; H302, H315, H319, H335; P261, P264, P271, P280, P301+P312, P305+P351+P338, P405, P501` |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of reach of children. Read label before use. If medical advice is needed, have product container or label at hand. |
| Flash point | Flash point: 206°C |
| Autoignition temperature | 300°C |
| Lethal dose or concentration | LD50 (oral, rat): 4300 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Nalidixic Acid: 4000 mg/kg (oral, rat) |
| NIOSH | QT2100000 |
| PEL (Permissible) | PEL = "10 mg/m3 |
| REL (Recommended) | 0.06 g |
| IDLH (Immediate danger) | 50 mg/m3 |
| Related compounds | |
| Related compounds |
Quinolone Ciprofloxacin Norfloxacin Oxolinic acid Pipemidic acid Enoxacin Flumequine |
